Ixico leverages patient technologies and introduces wearables

Guilio Cerroni, CEO of Ixico (LON:IXI) tells Proactive why the pharmaceuticals-serving business is expanding and why all of us longer lives also means it's a new and expanding area for investment.
Outlining his vision for a future growth strategy Guilio tells Proactive about new forays into wearable bio-sensors and human sleep patterns as focus shifts more towards patient outcomes and much less to drugs dispensing.

Established in 2004 and based in London, UK, at IXICO we put patients at the heart of what we do.
Our innovative technologies help those involved in researching and treating serious brain diseases to make rapid decisions and improve patient outcomes. While our clinical focus is predominantly dementia, we also support clinical studies for other disease areas in the field of neuro-degeneration and beyond.

Partners:

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for
listed biotech companies to interact with
institutional and highly capitalised investors. Headquartered in London, Biotech Capital is led by a team of Europe's
leading analysts and journalists, publishing daily content, covering all key movements
in the Biotechnology market.